Perspective Therapeutics, Inc. 8-K

What Happened

• Perspective Therapeutics, Inc. (CATX) filed a Form 8-K (Item 8.01) on May 21, 2026 reporting that it issued a press release the same day announcing certain interim results from its ongoing clinical trials.
• The company said those interim results will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, taking place May 29–June 2, 2026. The press release is attached to the 8-K as Exhibit 99.1 and is incorporated by reference.

Key Details

• Filing date: Form 8-K dated and signed May 21, 2026 (signed by CEO Johan (Thijs) Spoor).
• Event: Interim clinical trial results to be presented at ASCO 2026 (May 29–June 2, 2026, Chicago).
• Disclosure: Press release announcing the interim results filed as Exhibit 99.1 to the 8-K.
• Report section: Item 8.01 (Other Events); related exhibits listed under Item 9.01.

Why It Matters

• ASCO is a major oncology conference where clinical data are widely viewed by physicians, researchers, and investors; presenting interim results there is a formal step in communicating clinical progress.
• The 8-K does not disclose the specific data in the filing itself—investors should review the attached press release (Exhibit 99.1) and any ASCO presentation materials for details on efficacy, safety, or next steps that could affect the company’s clinical and commercial outlook.
• For retail investors, the timing and content of these clinical updates can influence sentiment and trading activity; monitor the ASCO presentation and follow-up company disclosures for material developments.